A detailed history of Charles Schwab Investment Management Inc transactions in Argenx Se stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 2,126 shares of ARGX stock, worth $914,265. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,126
Previous 1,087 95.58%
Holding current value
$914,265
Previous $413,000 102.66%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$356.95 - $413.29 $370,871 - $429,408
1,039 Added 95.58%
2,126 $837,000
Q4 2023

Feb 06, 2024

SELL
$338.91 - $506.01 $179,283 - $267,679
-529 Reduced 32.74%
1,087 $413,000
Q3 2023

Nov 08, 2023

BUY
$369.35 - $548.43 $322,442 - $478,779
873 Added 117.5%
1,616 $794,000
Q2 2023

Aug 09, 2023

BUY
$360.14 - $422.58 $267,584 - $313,976
743 New
743 $289,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $23.8B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.